Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: Effect on affinity and selectivity for dopamine D3 receptor

Bioorganic and Medicinal Chemistry

Volumn 17, Issue 11, 2009, Pages 3923-3933

  Brown, Dennis A ^a   Mishra, Manoj ^a   Zhang, Suhong ^a   Biswas, Swati ^a   Parrington, Ingrid ^b   Antonio, Tamara ^b   Reith, Maarten E A ^b   Dutta, Aloke K ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Dopamine; Dopamine receptor; Parkinson's disease

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 5 [[2 (4 ARYLPIPERAZIN 1 YL)ETHYL]PROPYLAMINO] 5,6,7,8 TETRAHYDRONAPHTHALEN 2 OL; 7 [[2 (4 ARYLPIPERAZIN 1 YL)ETHYL]PROPYLAMINO] 5,6,7,8 TETRAHYDRONAPHTHALEN 2 OL; [4 [2 [(5 HYDROXY 1,2,3,4 TETRAHYDRONAPHTHALEN 2 YL)PROPYLAMINO]ETHYL]PIPERAZIN 1 YL] (1H INDAZOL 3 YL)METHANONE; [4 [2 [(5 HYDROXY 1,2,3,4 TETRAHYDRONAPHTHALEN 2 YL)PROPYLAMINO]ETHYL]PIPERAZIN 1 YL] (1H INDOL 2 YL)METHANONE; AMIDE; BENZO[B]THIOPHEN 2 YL [4 [2 [(5 HYDROXY 1,2,3,4 TETRAHYDRONAPHTHALEN 2 YL)PROPYLAMINO]ETHYL]PIPERAZIN 1 YL]METHANONE; BENZOTHIOPHENE DERIVATIVE; CARBENE; D 328; D 332; D 334; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR STIMULATING AGENT; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HETEROCYCLIC COMPOUND; INDAZOLE DERIVATIVE; PIPERAZINE; SPIPERONE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; HUMAN; HUMAN CELL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANIMALS; CELL LINE; HETEROCYCLIC COMPOUNDS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; PIPERAZINES; PROTEIN BINDING; RECEPTORS, DOPAMINE D3; TETRAHYDRONAPHTHALENES;

EID: 65549122009     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.04.031     Document Type: Article

References (32)

1. Emilien G., Maloteaux J.-M., Geurts M., Hoogenberg K., and Cragg S. Pharmacol. Ther. 84 (1999) 133
2. Missale C., Nash S.R., Robinson S.W., Jaber M., and Caron M.G. Physiol. Rev. 78 (1998) 189
3. Kebabian J.W., and Calne D.B. Nature 277 (1979) 93
4. Giros B., Martres M.P., Sokoloff P., and Schwartz J.C. CR Acad. Sci. 311 (1990) 501
5. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., and Schwartz J.C. Nature 347 (1990) 146
6. Sunahara R.K., Guan H.C., O'Dowd B.F., Seeman P., Laurier L.G., Ng G., George S.R., Torchia J., Van Tol H.H., and Niznik H.B. Nature 350 (1991) 614
7. Van Tol H.H., Bunzow J.R., Guan H.C., Sunahara R.K., Seeman P., Niznik H.B., and Civelli O. Nature 350 (1991) 610
8. Gurevich E.V., and Joyce J.N. Neuropsychopharmacology 20 (1999) 60
9. Missale C., Nash S.R., Robinson S.W., Jaber M., and Caron M.G. Physiol. Rev. 78 (1998) 189
10. Park B.H., Fishburn C.S., Carmon S., Accili D., and Fuchs S. J. Neurochem. 64 (1995) 482
11. Foley P., Gerlach M., Double K.L., and Riederer P. J. Neural Transm. 111 (2004) 1375
12. Dutta A.K., and Le W. Exp. Opin. Ther. Patents 16 (2006) 1613
13. Braak H., Tredici K.D., Rüb U., de Vos R.A.I., Jansen Steur E.N.H., and Braak E. Neurobiol. Aging 24 (2003) 197
14. Fahn S. Adverse Effects of Levodopa (1992), Parthenon Publishing, Lancashire pp 89-112
15. Joyce J.N. Pharmacol. Ther. 90 (2001) 231
16. Sokoloff P., Diaz J., Le Foll B., Guillin O., Leriche L., Bezard E., and Gross C. CNS Neurol. Disord. Drug Targets 5 (2006) 25
17. Sanchez-Pernaute R., Jenkins B.G., Choi J.K., Iris Chen Y.C., and Isacson O. Neurobiol. Dis. 27 (2007) 220
18. Boeckler F., and Gmeiner P. Pharmacol. Ther. 112 (2006) 281
19. Luedtkea R.R., and Mach R.H. Curr. Pharm. Des. 9 (2003) 643
20. Woodward R., Coley C., Daniell S., Naylor L.H., and Strange P.G. J. Neurochem. 66 (1996) 394
21. Sartania N., and Strange P.G. J. Neurochem. 72 (1999) 2621
22. Varady J., Wu X., Fang X., Min J., Hu Z., Levant B., and Wang S. J. Med. Chem. 46 (2003) 4377
23. Perachon S., Schwartz J.C., and Sokoloff P. Eur. J. Pharmacol. 366 (1999) 293
24. Elsner J., Boeckler F., Heinemann F.W., Hubner H., and Gmeiner P. J. Med. Chem. 48 (2005) 5771
25. Dutta A.K., Fei X.-S., and Reith M.E.A. Bioorg. Med. Chem. Lett. 12 (2002) 619
26. Dutta A.K., Neisewander J., Fuchs R., and Reith M.E.A. Med. Chem. Res. 10 (2000) 208
27. Dutta A.K., Venkataraman S.K., Fei X.-S., Kolhatkar R., Zhang S., and Reith M.E.A. Bioorg. Med. Chem. 12 (2004) 4361
28. Biswas S., Zhang S., Fernandez F., Ghosh B., Zhen J., Kuzhikandathil E., Reith M.E., and Dutta A.K. J. Med. Chem. 51 (2008) 101
29. Biswas S., Hazeldine S., Ghosh B., Parrington I., Kuzhikandathil E., Reith M.E., and Dutta A.K. J. Med. Chem. 51 (2008) 3005
30. Ten Hoeve W., and Wynberg H. J. Org. Chem. 50 (1985) 4508
31. Park J.H., Choi J.K., Lee E., Lee J.K., Rhim H., Seo S.H., Kim Y., Doddareddy M.R., Pae A.N., Kang J., and Roh E.J. Bioorg. Med. Chem. 15 (2007) 1409
32. Cheng Y., and Prusoff W.H. Biochem. Pharmacol. 22 (1973) 3099